Anergis Granted U.S. Patent for Ragweed Allergy Vaccine AllerR
- Anergis receives notice of allowance from US Patent Office for patent on ultrafast treatment for ragweed allergies
EPALINGES, Switzerland, December 19, 2014 – Anergis, a company developing proprietary ultra-fast allergy vaccines, today announced that it received a notice of allowance from the US patent authorities for its patent covering composition and methods of use of its ragweed allergy product AllerR. AllerR is based on Anergis´ unique Contiguous Overlapping Peptide (COP) platform. COPs are pharmaceuticalgrade, long-peptide immunotherapeutics designed for an ultra-fast, safe and longlasting treatment of allergy patients.
Ragweed pollen is believed to be the most allergenic of all pollens. Allergies to ragweed pollen are mostly prevalent in the USA, where they affect an estimated 27 million patients, with a high degree of severity in many of them. Among others, ragweed allergies are a major cause of asthma. Fifty percent (50%) of allergic patients in the United States are sensitized to ragweed.
"Allowance of the patent on AllerR in the U.S. is a major milestone in broadening our international patent estate," said Christophe Reymond, Chief Scientific Officer of Anergis.
"The United States are the most important market for ragweed allergy treatments and this patent is of utmost strategic importance for the further clinical development of AllerR," added Vincent Charlon, Chief Executive Officer of Anergis.